1.	Don't stop the champions of research now: a brief history of head and neck pathology developments.
	Science.gov (United States)
	Thompson, Lester D R; Lewis, James S; Skálová, Alena; Bishop, Justin A
	2019-08-23  PubMed
	DOI: 10.1016/j.humpath.2019.08.017  ISSN: 0046-8177
	Keywords: Head;Neck;Salivary Gland Neoplasms;Oropharyngeal;Pathology, Surgical;Immunohistochemistry, Paranasal Sinus Neoplasms/Pathology;Molecular
	The field of Head and Neck Pathology was just developing 50years ago, but has certainly come a long way in a relatively short time. Thousands of developments in diagnostic criteria, tumor classification, malignancy staging, immunohistochemistry application and molecular testing have been made during this time, with an exponential increase in literature on the topics over the past few decades: There were 3506 articles published on head and neck topics in the decade between 1969 and 1978 (PubMed source), with a staggering 89266 manuscripts published in the most recent decade. It is daunting and impossible to narrow the more than 162000 publications in this field and suggest only a few topics of significance. However, the breakthru in this anatomic discipline has been achieved in three major sites: oropharyngeal carcinoma, salivary gland neoplasms, and sinonasal tract tumors. This review will highlight selected topics in these anatomic sites in which the most profound changes in diagnosis have occurred, focusing on the information that helps to guide daily routine practice of surgical pathology. Copyright © 2019. Published by Elsevier Inc.
2.	Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers.
	Science.gov (United States)
	Swiecicki, Paul L; Brennan, Julia R; Mierzwa, Michelle; Spector, Matthew E; Brenner, J Chad
	2019-08-01  PubMed
	DOI: 10.1002/lary.27725  ISSN: 0023-852X  Volume: 129  Issue: 8  Pages: 1836-1843
	Keywords: HPV, HRAS, biomarker, ccfDNA, ctDNA
	Head and neck squamous cell carcinomas are aggressive tumors that often present at advanced stage in difficult-to-biopsy regions of the head and neck. With the rapid move to analyze circulating tumor DNA (ctDNA) to either detect cancer or monitor disease progression and response to therapy, we have designed this article as a primer to understand the recent studies that support a transition to use these circulating biomarkers as a part of routine clinical care. Whereas some technical challenges still need to be overcome, the utility of ctDNA in cancer care is already evident from these early studies. Therefore, it is critical to understand recent advances in this area as well as emerging questions that need to be addressed as these biomarkers move closer to enhancing routine clinical care paradigms. Laryngoscope, 129:1836-1843, 2019. © 2018 The American Laryngological, Rhinological and Otological Society, Inc.
3.	Multifocal head and neck amyloidosis as a diagnostic clue of systemic lupus erythematosus (SLE): A case report.
	Science.gov (United States)
	Chen, Chih-Hao; Sun, Chuan-Hung
	2019-08-01  PubMed
	DOI: 10.1097/MD.0000000000016830  ISSN: 0025-7974  Volume: 98  Issue: 35  Pages: e16830
	Amyloidosis accounts for 2% of head and neck tumors. Amyloidosis that develops in the head and neck region is localized amyloidosis. Multifocal amyloidosis in the head and neck region is extremely rare. The patient presented to the clinic of otolaryngology with nasal obstruction, anosmia and left neck mass for several months. A left nasopharynx tumor was revealed under nasopharyngeal scope. Eosinophilic, proteinaceous material was revealed under a pathology scope in the nasopharynx tissue and neck tumor. Congo red staining demonstrated pale congophilic amorphous material with apple-green birefringence under cross-polarized light, and multifocal amyloidosis was diagnosed. Amyloidosis secondary to systemic lupus erythematosus (SLE) was confirmed after a series of investigations. The patient underwent local excision for multifocal amyloidosis without following management. To control underlying SLE, the patient accepted steroid pulse therapy and immunosuppressants. The patient eventually achieved disease remission. During the 6 months of follow-up in the outpatient department of otolaryngology and rheumatology, complications, recurrence of nasopharyngeal amyloidosis, and SLE flare-up were not observed. Head and neck amyloidosis involving the nasopharynx is a rare presentation of this disease. Head and neck multifocal amyloidosis should be taken as a hint of systemic disease. In head and neck amyloidosis, a comprehensive survey should be performed to clarify the underlying disease predisposing to amyloidosis and organ involvement.
4.	Current thinking in the management of adenoid cystic carcinoma of the head and neck.
	Science.gov (United States)
	Garg, Montey; Tudor-Green, Ben; Bisase, Brian
	2019-08-14  PubMed
	DOI: 10.1016/j.bjoms.2019.07.021  ISSN: 0266-4356
	Keywords: Follow-up in H&N ACC, Head and neck adenoid cystic carcinoma, Management of H&N ACC, Neck management in ACC
	Adenoid cystic carcinoma (ACC) is an aggressive, rare, malignant tumour that accounts for about 1% of all head and neck neoplasms and 10% of all salivary gland tumours. It is characterised by frequent local recurrences and distant metastases. Growth is slow but relentless, and progression poses a challenge to head and neck clinicians. Many small retrospective studies have described its clinical management, but the lack of multicentre, randomised, controlled trials has resulted in inconsistencies in management globally. We have focused on three key management-related controversies: the role of elective neck dissection (END) for the N0 neck; the role of adjuvant treatment or radiotherapy; and finally, the follow-up protocol, particularly cross-sectional surveillance imaging of the full body or chest computed tomography (CT) alone, and options for treatment if metastases are found. The paucity of published studies may reflect the inconsistencies that exist in the management of ACC of the head and neck in the UK. The collaboration of head and neck centres would, we think, help to correct the imbalance in these three domains of care. Copyright © 2019 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
5.	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
	Science.gov (United States)
	Haddad, Robert; Guigay, Joel; Keilholz, Ulrich; Clement, Paul M; Fayette, Jérôme; de Souza Viana, Luciano; Rolland, Frédéric; Cupissol, Didier; Geoffrois, Lionnel; Kornek, Gabriela; Licitra, Lisa; Melichar, Bohuslav; Ribaldo Nicolau, Ulisses; Rauch, Daniel; Zanetta-Devauges, Sylvie; Cohen, Ezra E W; Machiels, Jean-Pascal; Tahara, Makoto; Vermorken, Jan; Geng, Yuan; Zografos, Eleftherios; Gauler, Thomas
	2019-08-23  PubMed
	DOI: 10.1016/j.oraloncology.2019.08.004  ISSN: 1368-8375  Volume: 97  Pages: 82-91
	Keywords: Adherence, Afatinib, Feeding tube, HNSCC, Methotrexate, Recurrent/metastatic, Safety
	Patients with head and neck squamous cell carcinoma (HNSCC) can experience severe symptom burden and/or difficulty swallowing, leading to problems with treatment adherence/administration. In LUX-Head and Neck 1 (LH&N1; NCT01345682), second-line afatinib improved progression-free survival (PFS) versus methotrexate in patients with recurrent/metastatic HNSCC. We report adherence and safety across pre-specified and additional subgroups potentially linked to afatinib PFS benefit in LH&N1 (p16 status, smoking history), and afatinib adherence, safety and efficacy by administration (oral versus feeding tube; post-hoc analysis). Patients were randomized (2:1) to afatinib (40 mg/day) or intravenous methotrexate (40 mg/m 2 /week). Among 320 afatinib-treated and 160 methotrexate-treated patients, 83-92% and 76-92% (of patients with data available) across all subgroups took ≥80% of treatment. Across p16 status and smoking history subgroups, the most common treatment-related adverse events (AEs) were diarrhea (70-91%), rash/acne (72-84%), stomatitis (34-73%) with afatinib; and included stomatitis (39-100%), fatigue (22-50%), nausea (19-36%) with methotrexate. Dose reduction decreased AE incidence/severity. Baseline characteristics were generally similar between oral/feeding tube (n = 276/n = 46) groups. 89%/89% (of patients with data available) took ≥80% of assigned afatinib. Median PFS was 2.6 versus 2.7 months (hazard ratio: 0.997; 95% confidence interval: 0.72-1.38). The most common afatinib-related AEs were: rash/acne (74% versus 74%), diarrhea (73% versus 65%), stomatitis (40% versus 30%). Subgroup analyses of LH&N1 demonstrate that afatinib has predictable and manageable safety across patient subgroups, with high treatment adherence, and is effective via oral and feeding tube administration. Copyright © 2019 Elsevier Ltd. All rights reserved.
6.	Assessment of radiation dose and iodine load reduction in head-neck CT angiography using two scan protocols with wide-detector.
	Science.gov (United States)
	Zhao, Yongxia; Geng, Xue; Zhang, Tianle; Wang, Xiuzhi; Xue, Yize; Dong, Kexin
	2019-08-17  PubMed
	DOI: 10.3233/XST-190541  ISSN: 0895-3996
	Keywords: Gemstone spectral imaging, head-neck CT angiography, image quality, low iodine intake, radiation dose
	To compare image quality, radiation dose, and iodine intake of head-neck CT angiography (CTA) acquired by wide-detector with the gemstone spectral imaging (GSI) combination with low iodine intake or routine scan protocol. Three hundred patients who had head-neck CTA were enrolled and divided into three groups according to their BMI values: group A (18.5 kg/m2 ≦ BMI head-neck CT angiography than those yielded in routine scan protocol. It also enhances signal intensity of head-neck CTA and maintains image quality.
7.	Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
	Science.gov (United States)
	2019-08-15  ClinicalTrials.gov
	Cancer of Head and Neck
8.	Squamous cell carcinoma of the nasal cavity: A descriptive analysis of cases from the Head and Neck 5000 study.
	Science.gov (United States)
	Dale, O T; Pring, M; Davies, A; Leary, S; Ingarfield, K; Toms, S; Waterboer, T; Pawlita, M; Ness, A R; Thomas, S J
	2019-08-16  PubMed
	DOI: 10.1111/coa.13414  ISSN: 1749-4478
	Keywords: Nasal cavity, epidemiology, nasal mucosa, nasal septum, nasal surgical procedures, nose neoplasms, radiation, squamous cell carcinoma
	This paper aims to provide contemporary epidemiological data on squamous cell carcinoma (SCC) of the nasal cavity, which represents a rare type of head and neck cancer. A descriptive analysis of people with nasal cavity SCC treated with curative intent from the Head and Neck5000 study; a multicentre clinical cohort study of people from the UK with head and neck cancer. People with tumours of the nasopharynx, paranasal sinuses and other sub-sites of the head and neck were excluded. Demographic data and treatment details are presented for all participants. The main outcomes were overall survival and survival according to categories of characteristics (e.g. smoker vs non-smoker); these were explored using Kaplan-Meier plots. Thirty people with nasal cavity SCC were included in the study, of which most were male (67%) and current or ex-smokers (70%). The majority (70%) presented with early stage (T1/2, N0) tumours. Cervical lymph node metastases at presentation were rare, occurring in only one person. Nine people died during the follow up period (30%). Worse survival outcomes were seen in people with moderate or severe co-morbidities. This paper provides epidemiological data on nasal cavity SCC in the UK. Patterns of disease and survival outcomes are described, identifying high-risk groups. Further studies should explore whether primary treatment modality alters survival. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
9.	Factors driving frequent attendance at emergency departments for patients with head and neck cancer.
	Science.gov (United States)
	Tan, Aidan L; Iyer, Narayanan Gopalakrishna; Putri, Natascha; Nadkarni, Nivedita; Skanthakumar, Thakshayeni; Wong, Ting Hway; Tay, Gerald Ci An
	2019-08-18  PubMed
	DOI: 10.1002/hed.25916  ISSN: 1043-3074
	Keywords: access, cancer, emergency, frequent attenders, health care utilization
	Patients with head and neck cancer have a higher risk of emergency department (ED) frequent attender (FA). We hypothesized that FAs present with issues different from non-FAs. A retrospective cohort study was conducted on Singapore residents with head and neck cancers using de-identified registry merged with electronic medical record data. A competing risk regression analysis was performed to identify factors associated with FA. Aggregated primary diagnoses were compared for patients with and without FA risk factors. Thirteen percent of patients with head and neck cancer were FAs. FA risk factors were Charlson comorbidity index (3+), and socioeconomic status (SES). FAs had a higher proportion of respiratory infections. The spectrum of diagnosis was similar for patients with low and high SES. Current smokers had a greater proportion of respiratory complaints, relative to never smokers. Patients with greater comorbidity scores or higher SES were more likely to be FA. FAs were more likely to present with respiratory complaints, likely related to cancer treatment, or smoking status. © 2019 Wiley Periodicals, Inc.
10.	Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer.
	Science.gov (United States)
	Doescher, Johannes; Weissinger, Stephanie E; Schönsteiner, Stefan S; Lisson, Catharina; Bullinger, Lars; Barth, Thomas Fe; Leithäuser, Frank; Mueller-Richter, Urs; Laban, Simon; Hoffmann, Thomas K; Möller, Peter; Lennerz, Jochen K; Schuler, Patrick J
	2019-08-29  PubMed
	DOI: 10.2217/imt-2019-0041  ISSN: 1750-743X
	Keywords: crizotinib, decision making, head and neck cancer, imatinib mesylate, immunohistochemistry, oncopanel, precision oncology, trastuzumab
	Aim: In a prospective clinical initiative, we selected heavily pretreated head and neck carcinoma patients and assessed the clinical utility of a protein-based oncopanel for identification of potential targetable markers. Patients & methods: Tumor samples of 45 patients were evaluated using a 12-marker immunohistochemistry panel. The primary end point was the prevalence of potentially actionable markers. Results: At least one expressed marker in each case could be identified. We noted a high prevalence of EGFR (80%, 39/45) and MET (57.4%, 28/45). Three patients received oncopanel-based therapy with variable results. Conclusion: Despite the limited number of treated subjects, oncopanel analysis in end-stage head and neck cancer is operationally and technically feasible. Combination with targeted next generation sequencing might provide additional therapy options.
11.	MRI and PET-CT for Radiotherapy Planning for Head and Neck Cancer
	Science.gov (United States)
	2019-08-16  ClinicalTrials.gov
	Head and Neck Cancer
12.	To eat is to practice-managing eating problems after head and neck cancer.
	Science.gov (United States)
	Kristensen, Marianne Boll; Mikkelsen, Tina Broby; Beck, Anne Marie; Zwisler, Ann-Dorthe; Wessel, Irene; Dieperink, Karin B
	2019-08-24  PubMed
	DOI: 10.1007/s11764-019-00798-2  ISSN: 1932-2259
	Keywords: Eating problems, Head and neck cancer, Nutrition impact symptoms, Quality of life, Rehabilitation, Survivorship
	The purpose of this qualitative study was twofold: (1) to explore head and neck cancer (HNC) survivors' experiences of everyday life with eating problems after cancer treatment and (2) to explore their experiences of participating in a multidisciplinary residential rehabilitation program with a primary focus on physical, psychological, and social aspects of eating problems after treatment. Semi-structured focus group interviews were conducted with 40 Danish HNC survivors who participated in a 5-day residential rehabilitation program with follow-up after 3 months. The transcribed interviews were analyzed through qualitative content analysis. Physical nutrition impact symptoms and unmet needs for support were frequent. Participants experienced a feeling of loss due to impaired eating abilities. Eating had become an obligation or a training situation, and the eating problems challenged the relationship with their relatives when well-meaning encouragement was perceived as a pressure. Social eating was a challenge, and this often led to social withdrawal. The residential program was a safe and supportive environment to practice eating skills, and participants benefited from meeting peers. The program provided participants with knowledge and skills that many of them had been missing during and after treatment. Eating problems after treatment have substantial effects on the everyday life of HNC survivors. A multidisciplinary residential rehabilitation program may be beneficial to meet their rehabilitation needs. The results are useful for future planning of rehabilitation services and clinical studies that may contribute to improving current clinical practice and benefit HNC survivors.
13.	Revisiting the sternocleidomastoid flap as a reconstructive option in head and neck surgery.
	Science.gov (United States)
	Jones, L F; Farrar, E M; Roberts, D J H; Moor, J W
	2019-08-19  PubMed
	DOI: 10.1017/S0022215119001592  ISSN: 0022-2151  Pages: 1-5
	Keywords: Humans, Myocutaneous Flap, Neck Muscles, Otolaryngologic Diseases, Postoperative Complications, Reconstructive Surgical Procedures, Surgery, Surgical Flaps
	The sternocleidomastoid can be used as a pedicled flap in head and neck reconstruction. It has previously been associated with high complication rates, likely due in part to the variable nature of its blood supply. To provide clinicians with an up-to-date review of clinical outcomes of sternocleidomastoid flap surgery in head and neck reconstruction, integrated with a review of vascular anatomical studies of the sternocleidomastoid. A literature search of the Medline and Web of Science databases was conducted. Complications were analysed for each study. The trend in success rates was analysed by date of the study. Reported complication rates have improved over time. The preservation of two vascular pedicles rather than one may have contributed to improved outcomes. The sternocleidomastoid flap is a versatile option for patients where prolonged free flap surgery is inappropriate. Modern vascular imaging techniques could optimise pre-operative planning.
14.	Dosimetric parameters predictive of nasolacrimal duct obstruction after carbon-ion radiotherapy for head and neck carcinoma.
	Science.gov (United States)
	Kubo, Nobuteru; Kubota, Yoshiki; Kawamura, Hidemasa; Oike, Takahiro; Sakai, Makoto; Kumazawa, Takuya; Miyasaka, Yuhei; Okazaki, Shohei; Kobayashi, Daijiro; Sato, Hiro; Mizukami, Tatsuji; Musha, Atsushi; Shirai, Katsuyuki; Saitoh, Jun-Ichi; Yokoo, Satoshi; Chikamatsu, Kazuaki; Ohno, Tatsuya; Nakano, Takashi
	2019-08-19  PubMed
	DOI: 10.1016/j.radonc.2019.07.022  ISSN: 0167-8140
	Keywords: Carbon-ion radiotherapy, Dose–volume histogram, Head and neck tumors, Nasolacrimal duct obstruction, Non-squamous cell carcinoma
	Little information is available on the risk factors for nasolacrimal duct obstruction after radiotherapy for head and neck tumors. We investigated the incidence and predictive dosimetric parameters for nasolacrimal duct obstruction following carbon-ion radiotherapy for headand neck tumors. Twenty-eight patients with head and neck non-squamous cell carcinoma were analyzed in this single-institution prospective study. More than half of the tumors were located in the nasal cavity and maxillary sinus. Carbon-ion radiotherapy consisting of 57.6 or 64.0 Gy(relative biological effectiveness; RBE) in 16 fractions was administered. Nasolacrimal duct obstruction was recorded according to Common Terminology Criteria for Adverse Events version 4.0. Cutoff values were determined using receiver operating characteristic (ROC) curve analysis. VX indicates the volume irradiated with X Gy(RBE). The median follow-up period was 60.3 months. Incidences of Grade 1 and 2 nasolacrimal duct obstructions were 46% (13/28) and 7% (2/28), respectively; no Grade 3 or greater toxicities were recorded. Throughout the dose range, the volumes of the irradiated nasolacrimal ducts were significantly higher in the obstruction-positive patients than in the obstruction-negative patients (p 96% over the entire range of V10-V60. The incidence and predictive dosimetric parameters for nasolacrimal duct obstruction after carbon-ion radiotherapy were demonstrated in a prospective cohort. These data should help optimize carbon-ion radiotherapy treatments for patients with head and neck tumors. Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
15.	Malnutrition evaluation in head and neck cancer patients: Practice patterns among otolaryngologists and radiation oncologists.
	Science.gov (United States)
	Gill, Amarbir S; Kinzinger, Michael; Bewley, Arnaud F; Farwell, D Gregory; Moore, Michael G
	2019-08-12  PubMed
	DOI: 10.1002/hed.25909  ISSN: 1043-3074
	Keywords: diagnosis, malnutrition, management, screen, survey, tools
	Physician practice patterns regarding diagnosis and management of malnutrition in the head and neck cancer patient population are not well studied. A 17-question survey was distributed to 1392 members of the American Head and Neck Society (AHNS). The impact of hospital type, fellowship training, experience, and specialty was assessed. Among AHNS members, there were 124 total respondents (9% response rate), including both otolaryngologists and radiation oncologists. Respondents strongly agreed (90%) that malnutrition negatively impacts patient outcomes. The majority (63%) felt comfortable screening for malnutrition, but 13% reported no routine assessment of malnutrition; 57% were unfamiliar with relevant guidelines. Barriers to screening included lack of familiarity with screening tools/guidelines, lack of time, and lack of access to dietitian. Although there was a strong consensus among respondents that the identification and management of malnutrition among head and neck cancer patients is critical, familiarity with relevant guidelines was poor. © 2019 Wiley Periodicals, Inc.
16.	Glomus tumors of the head and neck: thirteen years' institutional experience and management.
	Science.gov (United States)
	Tokgöz, Sibel Alicura; Saylam, Güleser; Bayır, Ömer; Keseroğlu, Kemal; Toptaş, Gökhan; Çadallı Tatar, Emel; Akın, İstemihan; Korkmaz, Mehmet Hakan
	2019-08-27  PubMed
	DOI: 10.1080/00016489.2019.1655588  ISSN: 0001-6489  Pages: 1-4
	Keywords: Glomus tumors, complication, head and neck surgery, paraganglioma
	Background: Head and neck paragangliomas are slowly growing benign tumors and they originate from specialized neural crest cells. Aims/objectives: This study aimed to express the safety of paraganglioma surgery regarding complications, treatment, and outcomes of patients with head and neck glomus tumors. Materials and methods: Medical records of patients who were operated because of head and neck paraganglioma between 2006 and 2016 were reviewed. Results: The study group consisted of 49 patients (M/F: 6/43). The patients were distributed as follows: 22 glomus caroticum (GC) (44.8%), 8 glomus jugulare (GJ) (16.3%), 10 glomus tympanicum (GT) (20.4%), 4 glomus vagale (GV) (8.1%), 2 GC + GV (4%), 2 bilateral GC (4%) and 1 thyroidal glomus tumor (2%). All GC and GV tumors were resected via cervical approach. Three of GJ tumors were resected through transmastoid approach while five of them were resected through both transmastoid and cervical approach. Nine GT tumors were resected via transmastoid approach. One patient received cyberknife. Thyroid paraganglioma was diagnosed incidentally after total thyroidectomy. Mean follow-up period was 61.92 ± 35.11 months (1-124 m). Conclusions and significance: The choice of treatment depends on the size, location and biologic activity of tumor as well as the physical condition of the patient. Our results show that glomus tumors can be resected with low mortality and morbidity rates due to developing imaging and microsurgical methods.
17.	Risk and outcomes for second primary human papillomavirus-related and -unrelated head and neck malignancy.
	Science.gov (United States)
	Adjei Boakye, Eric; Buchanan, Paula; Hinyard, Leslie; Stamatakis, Katie; Osazuwa-Peters, Nosayaba; Simpson, Matthew C; Schootman, Mario; Piccirillo, Jay F
	2019-08-01  PubMed
	DOI: 10.1002/lary.27634  ISSN: 0023-852X  Volume: 129  Issue: 8  Pages: 1828-1835
	Keywords: Epidemiology, Head and neck squamous cell carcinoma, Surveillance, and End Results (SEER), human papillomavirus, risk factor, second primary malignancy, survival
	To 1) examine the characteristics of patients who develop second primary malignancies (SPMs) from an index human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and HPV-unrelated HNSCC and to 2) compare overall survival between those with HPV-related and HPV-unrelated index HNSCC among patients who develop SPM. Retrospective cohort analysis. A retrospective study was conducted of 113,259 patients who were diagnosed with HNSCC from 2000 to 2014. SPM was defined as the first subsequent primary cancer occurring at least 2 months after index cancer diagnosis, and HPV-relatedness was based on whether patients' index HNSCC was potentially HPV-related or HPV-unrelated. Multivariable Fine and Gray (FG) competing-risks regression models were used to estimate factors associated with risk of SPM by HPV-relatedness. Among patients with SPM, an adjusted Cox proportional hazards (PH) regression model was used to assess the association between HPV-relatedness and survival. Approximately 13,900 patients (12.3%) developed SPM. In the FG model, patients with HPV-unrelated HNSCC had a 15% higher risk of developing SPM (adjusted hazard ratio: 1.15, 95% confidence interval: 1.10-1.20) than those with potentially HPV-related HNSCC, but the same characteristics were associated with SPM development. In the Cox PH model, patients with SPM whose index HNSCC was HPV-unrelated had higher risk of death than those whose index HNSCC was potentially HPV-related (adjusted hazard ratio: 1.06; 95% confidence interval: 1.02-1.11). Patients with HPV-unrelated HNSCC have a higher risk of SPM development than do those with HPV-related HNSCC. Effective secondary disease-prevention strategies should be established to improve long-term patient outcomes. NA Laryngoscope, 129:1828-1835, 2019. © 2018 The American Laryngological, Rhinological and Otological Society, Inc.
18.	Diagnosis of Sarcopenia in Head and Neck Computed Tomography: Cervical Muscle Mass as a Strong Indicator of Sarcopenia
	KoreaMed
	Ufuk, Furkan Herek, Duygu Yüksel, Doğangün
	2019-08-01  Clinical and Experimental Otorhinolaryngology
	DOI: 10.21053/ceo.2018.01613  ISSN: 1976-8710  Volume: 12  Issue: 3
	Full Text Available OBJECTIVES: Patients with head and neck cancer (HNC) have a high risk of sarcopenia, which is associated with poor prognosis. Skeletal-muscle area and index at the third lumbar (L3) vertebra level (L3MA and L3MI) are recommended for the detection of sarcopenia. However, L3 level is not included in many imaging protocols and there are no data for optimal levels and cutoffs for the diagnosis of sarcopenia in head and neck computed tomography (HNCT) scans. Our aim was to assess the relationship between cervical paravertebral muscle values and L3MI and to investigate optimal level to diagnose sarcopenia on HNCTs.
19.	Fatigue in patients with head and neck cancer undergoing radiation therapy: a prospective study*
	Science.gov (United States)
	2019-08-19  PubMed Central
	DOI: 10.1590/1518-8345.2813-3168  ISSN: 0104-1169  Volume: 27
	Keywords: Nursing, Radiotherapy, Fatigue, Cancer, Quality of Life, Head and Neck Neoplasms
	Objective to identify the frequency of fatigue and domains affected in patients with head and neck cancer undergoing radiation therapy, at the beginning, middle and end of treatment. Method longitudinal and prospective study of quasi-experimental design, involving 60 patients with head and neck cancer. It should be highlighted that this article will address only the data of the Control Group. The dependent variables were collected through interview, using the revised Piper Fatigue Scale, which is a multidimensional instrument that assesses global, behavioral, affective and sensory/psychological domains. Data analysis was based on absolute and relative frequencies. Results there was a predominance of males, age group between 41-60 years, low level of education and in regular use of alcohol and cigarettes. All domains in the fatigue scale had their scores increased, presenting median values of greater magnitude in Time 2 and Time 3, when compared to the Time 1 values, indicating an increase in fatigue levels during radiation therapy. Conclusion fatigue increased in the course of the radiation therapy, having all domains affected. Therefore, its evaluation throughout the treatment is important, as fatigue is a common and debilitating symptom on cancer patients. PMID:31432921
20.	Minimum Standardized Uptake Value from Quantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography for Evaluation of Femoral Head Viability in Patients with Femoral Neck Fracture
	KoreaMed
	Ryoo, Hyun GeeLee, Won WooKim, Ji YoungKong, Eunjung Choi, Woo HeeYoon, Joon Kee,
	2019-08-01  Nuclear Medicine and Molecular Imaging
	DOI: 10.1007/s13139-019-00600-2  ISSN: 1975-129X  Volume: 53  Issue: 4
	Full Text Available PURPOSE: Bone single-photon emission computed tomography/computed tomography (SPECT/CT) has been widely used for evaluation of femoral head viability in patients with femoral neck fracture. The current study aimed to investigate utility of standardized uptake value (SUV) from quantitative bone SPECT/CT for assessment of femoral head viability.